In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure ( EMPHASIS-HF ) , aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms ( New York Heart Association class II ) and chronic systolic heart failure ( HF ) .